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Antiviral treatment of immunocompromised patients 
with prolonged influenza virus infection can lead to 
multidrug resistance. This study reveals the selection 
of antiviral resistance mutations in influenza A(H1N1)
pdm09 virus in an immunocompromised patient dur-
ing a 6-month period. The patient was treated with two 
courses of oseltamivir (5 days and 2 months, respec-
tively), with the first course starting at symptom onset, 
and subsequently zanamivir (2 months and 10 days, 
respectively). Respiratory samples were investigated 
by Sanger and next generation sequencing (NGS) and, 
for NGS data, low-frequency-variant-detection analy-
sis was performed. Neuraminidase-inhibition tests 
were conducted for samples isolated in Madin-Darby 
canine kidney cells. In a sample collected 15 days after 
the end of the first treatment with oseltamivir (Day 
20 post-symptom onset), oseltamivir resistance was 
detected (mutation H275Y with 60.3% frequency by 
NGS). Day 149 when the patient had almost completed 
the second zanamivir treatment, mixes of the follow-
ing resistance mutations were detected; H275Y(65.1%), 
I223R(9.2%), and E119G(89.6%), accompanied by 
additional mutations, showing a more complex viral 
population in the long-term treated patient. Two sam-
ples obtained on Day 151 from bronchoalveolar lavage 
(BAL) and nasopharyngeal swab, respectively, showed 
different mutation profiles, with a higher frequency 
of antiviral resistance mutations in BAL. The results 
emphasise the importance of timely antiviral resist-
ance testing both for treatment of individual patients 
as well as for preventive measures to control the devel-
opment and transmission of antiviral resistant viruses.
Introduction
Influenza virus is the cause of annual seasonal epi-
demics worldwide, and leads to high morbidity in the 
population. Severe disease and deadly outcome due 
to influenza virus are recognised in the defined risk 
groups, in particular elderly persons > 65 years of age 
and immunocompromised patients. Influenza is nor-
mally an acute self-limiting disease with a duration of 
5 to 7 days, however, in immunocompromised patients 
prolonged infections lasting several months have been 
reported [1-4]. Prevention of severe influenza disease 
is mainly based on immunisations with split vaccines 
which are produced annually to accommodate the 
changing antigenicity of seasonal epidemic viruses 
[5,6]. The effect of vaccination in immunocompromised 
patients is questionable and this is why other modes 
of prevention and/or treatment often are considered for 
this risk group [7-12]. For treatment of influenza viruses 
only a few antiviral drugs are available; the neuramini-
dase (NA) inhibitors and the matrix-2 (M2)-ion channel 
inhibitors. The current circulating epidemic influenza 
viruses harbour natural resistance towards the M2-ion 
channel inhibitors therefore these are not an option 
for treatment [13-15]. The NA inhibitors bind to the 
NA surface protein and prevent it from facilitating the 
release of new virus particles from an infected cell [16]. 
In Denmark, two different NA inhibitors are approved 
and available for treatment of influenza: oseltamivir 
(Tamiflu) and zanamivir (Relenza). Oseltamivir is the 
drug of choice for treatment due to its easy oral admin-
istration whereas zanamivir (intravenous or inhalation) 
is often used when the effect of oseltamivir is limited, 
e.g. in case of development of resistance. In the NA 
gene of the H1N1 viruses a range of amino acid muta-
tions are recognised to confer reduced inhibition by 
NA inhibitors [16-18]. Among these, two well character-
ised mutations are the H275Y mutation which results 
in viruses with highly reduced inhibition by oseltamivir 
and the I223R mutation which results in reduced inhibi-
tion by both oseltamivir and zanamivir [16,17].
Antiviral treatment of immunocompromised patients 
with prolonged influenza virus infection can lead to 
multidrug-resistant influenza quasispecies in the same 
patient [1]. We describe how the emergence of such 
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virus variants poses challenges in the combat of a 
severe influenza infection in a Danish patient treated 
with antivirals. The patient had sustained shedding of 
influenza A(H1N1)pdm09 virus for 6 months and was 
treated with oseltamivir and subsequently zanamivir. 
Antiviral resistance mutation profiles were evaluated 
using conventional Sanger sequencing and next gen-
eration sequencing (NGS).
Methods
Case and samples 
The immunocompromised patient had chronic lympho-
cytic leukaemia (CLL) and was aged between fifty and 
sixty years. Influenza-vaccination status was unknown. 
Respiratory samples were obtained at frequent inter-
vals during the course of infection. These included 
nasopharyngeal swabs, bronchoalveolar lavage (BAL), 
and expectorates, which were used for diagnostic of 
influenza virus and detection of antiviral resistance. 
The first sample was collected at the onset of respira-
tory symptoms. Since it tested positive for influenza 
A(H1N1)pdm09, oseltamivir treatment was immediately 
started. Approximately 3 months later, a first sam-
ple for antiviral resistance testing was submitted to 
the National Influenza Center, Denmark. Subsequent 
samples were then also investigated, as well as those 
collected before this time point, which were retrospec-
tively analysed. The overall treatment consisted of two 
courses of oral oseltamivir, one course of inhalation 
therapy with zanamivir, and a compassionate-use pro-
gramme with intra venous (i.v.) zanamivir (Figure).
Virus detection
Total nucleic acid was extracted using 200 µL of sam-
ple material and the MagNA Pure LC Total Nucleic Acid 
Isolation Kit on the MagNapure 96/32 (Roche).
A multiplex real-time reverse transcription-PCR 
(RT-PCR) detecting the influenza A matrix (M) gene as 
well as H1N1pdm09 NA gene was performed using the 
MX3005P Stratagene platform according to the proto-
col designed by the National Influenza Center Denmark 
(Statens Serum Institut, Copenhagen, Denmark). The 
cycle threshold (Ct) values for the M-gene were used 
as a relative measure of viral load.
Virus isolation
Isolation of influenza virus was performed in dupli-
cates in Madin-Darby canine kidney (MDCK) cells using 
standard methods [19]. Because of challenges caused 
by poor constitution/lack of sample material and dif-
ficulties in cultivating the virus in ca 50% of samples, 
it was not possible to report viral load in PFU/mL or 
TCID50.
Due to loss of the zanamivir antiviral resistance muta-
tions during cell-propagation, experimentation with 
addition of zanamivir and oseltamivir in different 
concentrations and combinations was performed in 
an attempt to rescue the mutated virus. Virus growth 
medium was supplemented with zanamivir and 
oseltamivir at the following concentrations: 1 µM, 0.1 
µM, 0.01 µM, 0.001 µM. The two drugs were mixed or 
added alone to the virus growth medium in the differ-
ent concentrations.
Detection of the H275Y mutation using allele-
specific real-time reverse transcription-PCR
For rapid initial screening of the oseltamivir resistance 
conferring single nt polymorphism (SNP) mutation 
H275Y, an allele specific real-time RT-PCR was applied 
to the samples, following a protocol designed by the 
National Influenza Center Denmark (Statens Serum 
Institut, Copenhagen, Denmark).
Figure 
Time line of the treatment course of an immunocompromised patient with influenza with oseltamivir and zanamivir and of 
development of antiviral resistance mutations, Denmark, 2014
Day 0 1 month 2 months 3 months 4 months 5 months
1st 
oseltamivir
5 days
2nd oseltamivir
Day 20 to 81
Inhalation zanamivir
Day 88 to 143
Intravenous zanamivir
Day 143 to 153 Patientdies
Onset of respiratory
symptoms
A(H1N1)pdm09 virus 
of wild type detected
Antiviral treatment 
Day 95 and 96
1st sample tested
for antiviral resistance
H275Y
Day 132
H275Y + I223R/I
Day 149
E119G+I223R/I+H275Y/H
Day 20
mix 275Y/H
Day 27
H275Y
Day 151
BAL: E119G/E+I223R/I+H275Y
nasopharynx: E119E+I223R/I+H275H/Y
Detection of resistance mutation
BAL: bronchoalveolar lavage.
3www.eurosurveillance.org
Table 1
Amino acid substitutions in the influenza A(H1N1)pdm09 virus neuraminidase, reported to be involved in antiviral 
resistance [16], which were found in an immunocompromised patient treated with oseltamivir and zanamivir, Denmark 2014
Sample 
number: 
cells for virus 
culture and 
antiviral 
added if any
Day Origin of the sample
M-gene 
Ct-value Reads NGS
Sequencing 
method
Amino acid position and type in the consensus sequence of reference virus A/
California/07/2009; for comparison to the sequence of the virus infecting the 
patient
117a 118b 119b 136a 199b 223b 247a 275b 402b
I R E Q D I S H Y
1 0 Nasopha. 29.55 1,525,617
NGS (%) * * * * * * * * *
S * * * * * * * * *
2 20 Nasopha. 27.47 914,914
NGS (%) M (1.04) * * * * R (3.4) * Y (60.3) *
S * * * * * * * Y/H *
3 27 Nasopha. 31.5 4,483
NGS (%) * * * * * * * Y (> 99) *
S n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
4
95
BAL 25.88 n.d.
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * * Y *
4: 2MDCK Z Cell culture 34.35 1,216,299
NGS (%) * * G (24.3) * * * N (72.4) Y (> 99) *
S * * E/G * * * S/N Y n.d.
4: 2MDCK Z/O Cell culture 34.53 1,566,074
NGS (%) * * G (30.4) * G (1.6) *
N 
(42.6) Y (> 99) *
S * * E/G * * * S/N Y *
5
96
BAL 26.53 n.d.
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * S/N Y *
5: 3MDCK Cell culture 16.82 1,458,499
NGS (%) * * * * * * * Y (> 99) N (1.47)
S * * * * * * * Y *
5: 4MDCK Z Cell culture 22.96 1,233,121
NGS (%) * * * * * * * Y (> 99) *
S * * * * * * n.d. Y *
5: 4MDCK Z/O Cell culture 23.72 n.d.
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * * Y *
6
132
Expectorate 28.83 1,132,787
NGS (%) * * * * * R (53.4) R (1.1) Y (> 99) *
S * * * * * I/R * Y *
6: 2MDCK Cell culture 18.73 1,012,035
NGS (%) * * * * * * * Y (> 99) *
S * * * * * * * Y *
6: 2MDCK Z Cell culture 32.01 2,955,354
NGS (%) * * * * * R (75.3) * Y (> 99) *
S * * * * * I/R * Y *
6: 2MDCK Z/O Cell culture 34.13 641,179
NGS (%) * * * * * R (49.3) I (1.9) Y (> 99) *
S * * * * * I/R * Y *
6: 3MDCK Cell culture 18.71 1,255,140
NGS (%) * * * * * * * Y (> 99) *
S * * * * * * * Y *
7 149 Expectorate 32.61 1,413,804
NGS (%) L (7.04)/M (9.3) * G (89.6) * * R (9.2) N (6.7)
Y 
(65.1) *
S * * G/E * * * * H/Y *
8
151
BAL 36.99 3,036,466
NGS (%) * * G (35.9) * * R (51.8) * Y (88.2) *
S * * E/G * * I/R * Y *
8: 2MDCK Cell culture 17.93 1,823,988
NGS (%) * * * * * * * Y (> 99) *
S * * * * * * * Y *
8: 3MDCK Cell culture 15.94 1,274,826
NGS (%) * * * * * * * Y (> 99) *
S * * * * * * * Y *
9 151 Nasopha. 36.56 1,699,587
NGS (%) * M (1.1) G (7.3)
K 
(2.5) * R (34.2) N (6.2)
Y 
(74.9) *
S * * * * * I/R * H/Y *
AA: amino acid; BAL: bronchoalveolar lavage; Ct-value: cycle threshold value obtained by real-time reverse transcription-PCR; M-gene: matrix gene; MDCK: 
Madin-Darby canine kidney cells; nasopha.: nasopharyngeal swab; n.d.: no data; NGS: next generation sequencing; S: Sanger sequencing; z: virus isolate 
cultivated with 1µM zanamivir; z/o: virus isolate cultivated with 1µM zanamivir and 0.1µM oseltamivir.
The samples are ordered and numbered in the chronological order of collection. When the virus was isolated in culture from a sample, the types of cells and 
the number of passages are indicated next to the sample number. The Table also depicts the type of sample material, which was initially collected. NGS and 
S-sequencing of samples or the respective virus isolates were performed to infer the AA sequence. When more than one AA type was inferred at a given 
sequence position by NGS, the frequency of each AA identified is provided (in the rows: NGS (%)). The * indicates that the AA is identical to the reference virus 
A/California/07/2009(H1N1pdm09) consensus sequence.
a Non-active site of the neuraminidase enzyme. 
b Active site of the neuraminidase enzyme. 
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Table 2
Influenza A(H1N1)pdm09 virus neuraminidase amino acid substitutions proposed to be involved in viral fitness and related 
to antiviral resistance and cell adaptation, which were found in samples from an immunocompromised patient treated with 
oseltamivir and zanamivir, Denmark 2014
Sample Day Material Reads NGS Sequencing method
Amino acid position and type in the consensus sequence of reference virus A/
California/07/2009; for comparison to the sequence of the virus infecting the patient
83 86 147 149 173 232 241 248 313 314 416 438
V A G I R A I D Q I D T
1 0 Nasopha. 1,525,617
NGS (%) * * * * * * * * * * * *
S * * * * * * * * * * * *
2 20 Nasopha. 914,914
NGS (%) * * * * * * * * * * N (20.4) *
S * * * * * * * * * * * *
3 27 Nasopha. 4,483
NGS (%) * * * * * * * * * * * *
S n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
4
95
BAL n.d 
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * * * * * * *
4: 2MDCK 
Z Cell culture 1,216,299
NGS (%) * * R (2) * * * V (7.7) N (1.6) * * * *
S * * * * * * * * * * n.d. n.d.
4: 2MDCK 
Z/O Cell culture 1,566,074
NGS (%) * * * * * * V (4.5) N (1.9) * T (3.2) *
A 
(4.5)
S * * * * * * * * * * * *
5
96
BAL n.d.
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * * D/(N) * * * *
5: 3MDCK Cell culture 1,458,499
NGS (%) * * * * * * V (10.6) * * * * *
S * * * * * * * * * * * *
5: 4MDCK 
Z Cell culture 1,233,121
NGS (%) * * * * * * V (4.8) * * * * *
S * * * * * * * * * * * *
5: 4MDCK 
Z/O Cell culture n.d.
NGS (%) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
S * * * * * * * * * * * *
6
132
Expectorate 1,132,787
NGS (%) I (44.9) * R (33.4)
T 
(6.6) * * V (5.1) *
K 
(3.5) * N (4.1) A (1.8)
S V/I * G/(R) * * * * * * * * *
6: 2MDCK Cell culture 1,012,035
NGS (%) * T (71) * T (23)
K 
(30) * V (3.8) * K (70) * * *
S * T * * R/K * * * K * * *
6: 2MDCK 
Z Cell culture 2,955,354
NGS (%) I (14.8) * R (15.4) T (4.1) * * V (1.7) * K (4.1) * N (2.7) *
S V/(I) * * * * * * * * * * *
6: 2MDCK 
Z/O Cell culture 641,179
NGS (%) I (41.6) * R (40) T (6.9) * * V (4) *
K 
(2.6) * N (1.1) *
S V/I * G/R * * * * * * * * *
6: 3MDCK Cell culture 1,255,140
NGS (%) * T (80) * T (16)
K 
(21) * V (3.8) * K (79) * * *
S * T * * R/K * * * K * * *
7 149 Expectorate 1,413,804
NGS (%) I (4.6) * R (2) * * V (21.8) V(3) N (46)
R 
(2.8)
T 
(17.8) *
A 
(56.9)
S * * * * * * * D/N * * * T/A
8
151
BAL 3,036,466
NGS (%) I (6.1) * R (21.3) * * V (14) V (8.1) N (9.2) * T (5.6) * A (3)
S * * * * * * * * * * * *
8: 2MDCK Cell culture 1,823,988
NGS (%) * T (62) * T (32)
K 
(40) * V (3.1) * K (60) * * *
S * T * I/(T) R/K * * * Q/K * * *
8: 3MDCK Cell culture 1,274,826
NGS (%) * T (74) * T (22)
K 
(29) * V (5.3) * K (71) * * *
S * T * * R/K * * * K * * *
9 151 Nasopha. 1,699,587 NGS (%) * * * * * V (15.3) V (5.4)
N 
(44.9)
R 
(9.9)
T 
(8.8) *
A 
(2.5)
S * * * * * * * D/N * * * *
Proposed functiona f c f u c f u f c f u f
AA: amino acid; BAL: bronchoalveolar lavage; Ct-value: cycle threshold value obtained by real-time reverse transcription-PCR; nasopha.: nasopharyngeal swab; n.d.: no data; 
MDCK: Madin-Darby canine kidney cells; NGS: next generation sequencing; S: Sanger sequencing; z: virus isolate cultivated with 1µM zanamivir; z/o: virus isolate cultivated 
with 1µM zanamivir and 0.1µM oseltamivir.
The samples are ordered and numbered in the chronological order of collection. When the virus was isolated in culture from a sample, the type of cells and the number of 
passages are indicated next to the sample number. The Table also depicts the type sample material, which was initially collected. NGS and Sanger sequencing of samples or 
the respective virus isolates were performed to infer the AA sequence. When more than one AA type was found at a given sequence position by NGS, the frequency at which 
each AA identified is provided (in the rows: NGS (%)). The * indicates that the AA is identical to the reference virus A/California/07/2009(H1N1pdm09) consensus sequence.
a f: fitness related to antiviral resistance; c: cell adaptation due to cultivation; u: unknown. 
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Sequencing of the neuraminidase gene and 
minority variant analysis
Full-length Sanger sequencing of the NA gene was per-
formed by RT-PCR using in-house primers and Big Dye 
chemistry on an ABI3500 capillary sequencer (Applied 
Biosystems) and was analysed using Bionumerics 
(Applied Maths, Belgium) and Molecular Evolutionary 
Genetics Analysis (MEGA)6 software.
NGS was performed using NexteraXT DNA sample prep-
aration kit (Illumina) and subsequent sequencing on 
the MiSeq (Illumina).
Minority variant analysis was performed on NGS data 
using CLC Genomics Workbench version 8 (Qiagen, 
Germany).
Neuraminidase inhibition assays
Oseltamivir and zanamivir inhibition of the NA activ-
ity of virus isolates was assessed using the NA-Fluor 
Influenza Neuraminidase Assay Kit from Applied 
Biosystems (Life technologies). The reference virus 
A/California/07/2009(H1N1pdm09) was used as wild 
type control. The mean 50% inhibitory concentration 
(IC) was calculated according to the kit protocol and 
as the fold-change to the wild-type control virus. World 
Health Organization (WHO) criteria for determination 
of inhibition by oseltamivir and zanamivir were used to 
evaluate the level of antiviral resistance [20]. Normal 
inhibition (NI) is < 10 IC50 fold change compared with 
wild-type virus, reduced inhibition (RI) 10–100, and 
highly reduced (HR) > 100.
Results
Genotypic antiviral resistance testing results
The patient was treated with oseltamivir immediately 
after diagnosis. The sample from day 0, the same day 
the first oseltamivir treatment was initiated, was retro-
spectively analysed for antiviral resistance mutations. 
At this point there was no antiviral resistance muta-
tions recognised (Table 1).
Despite the first oseltamivir treatment lasting 5 days, 
the patient continued to have symptoms and influenza 
A(H1N1)pdm09 positive samples. As a result, a second 
oseltamivir treatment was initiated at 20 days post-
symptom onset (Day 20). Samples collected 15 days 
after termination of the 1st oseltamivir treatment (Day 
20) and 7 days after initiation of the 2nd oseltamivir 
treatment (Day 27), were retrospectively investigated 
as well. Both contained virus with the H275Y mutation 
at a frequency of 60.3% (day 20) and > 99% (day 27). Day 
96, one week after initiation of inhalation therapy with 
zanamivir and three months after initiation of symp-
toms including two courses of treatment with oseltami-
vir another sample was collected and submitted for 
antiviral resistance testing to the National Influenza 
Center. The sample contained influenza A(H1N1)pdm09 
virus with the H275Y mutation and Sanger sequencing 
revealed an additional S247N mutation(Figure, Table 
1). Day 132, one and a half month after initiation of 
inhalation therapy with zanamivir a sample was inves-
tigated for further development of antiviral resistance 
mutations. At this time point the H275Y mutation was 
still recognised, however, a mixed population with 
the I223R/I mutation was also observed by Sanger 
sequencing. The I223R substitution was later confirmed 
by NGS with a frequency of 53.4% (Figure, Table 1).
As no clinical improvement of the patient was obtained, 
i.v. zanamivir treatment was carried out for 10 days. 
Samples from Day 149 and 151, six and eight days 
after initiation of i.v. zanamivir treatment, respectively, 
revealed a mixed population of virus with wild type and 
resistant-conferring residues at position 275 (H275Y/H) 
as well as at position 223 (I223R/I) using Sanger 
sequencing (Figure, Table 1). By NGS a more differenti-
ated viral population was observed involving a range of 
mutations (Table 1 and 2). Interestingly, a discrepancy 
was discovered between two samples collected on day 
151. In a sample obtained as BAL there was a higher 
frequency of the major resistance-inducing mutations 
(E119G: 35.9%, I223R: 51.8%, and H275Y: 88.2%) com-
pared with a sample obtained as nasopharyngeal swab 
(E119G: 7.3%, I223R: 34.2% and H275Y:74.9%). The 
nasopharyngeal swab on the other hand showed three 
Table 3
Results from neuraminidase inhibition assay of virus isolates, Denmark, 2014 
Virus isolate Amino acid substitution 
Mean IC50 
(nM) for 
oseltamivir 
Fold change to 
wild type for 
oseltamivir 
Conclusion:  
oseltamivir 
Mean IC50 
(nM) for 
zanamivir 
Fold change to 
wild type for 
zanamivir 
Conclusion:  
zanamivir 
5: 3MDCK H275Y 440 880 HRI 0.03 2.1 NI
6: 2MDCK H275Y 245.8 491.6 HRI 0.03 2.13 NI
8: 3MDCK H275Y 250.9 501.8 HRI 0.02 1.59 NI
A/California/07/2009 Wild type 0.5 Ref NI 0.01 Ref NI
HRI: highly reduced inhibition; IC50: 50% inhibitory concentration; MDCK: Madin-Darby canine kidney cells; NI: normal inhibition; ref: 
reference.
The mean IC50 is indicated in nM for both oseltamivir and zanamivir as well as the fold change to wild type control virus A/
California/07/2019(H1N1pdm09).
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additional mutations related to antiviral resistance, 
however, at a low frequency (R118M: 1.1%, Q136K: 
2.5%, and S247N: 6.2%). 
Genotypic antiviral resistance testing of cell 
propagated samples 
It was possible to propagate virus from four of the sam-
ples in MDCK cells. During propagation it was observed 
by sequencing that the antiviral resistance mutation 
I223R found in the original sample materials was lost 
after cell propagation, while new mutations indicative 
of cell adaptation occurred at positions A86T, R173K, 
and Q313K (Table 1 and 2). In an attempt to preserve 
the antiviral resistance mutations, the growth medium 
was supplemented with zanamivir alone or zanamivir 
and oseltamivir. For two virus isolates propagated with 
antivirals in the growth medium it was possible to res-
cue viruses with the I223R mutation (Table 1).
Phenotypic antiviral resistance testing results
Due to a low amount of sample material it was not 
possible to perform NA inhibition tests on any of the 
samples directly. Three virus isolates carrying only the 
H275Y mutation had mean IC50s against oseltamivir, 
which were ca 500–900 fold higher than the wild type 
H275 strain A/California/07/2009(H1N1pdm09) virus, 
thereby showing highly reduced inhibition (Table 3). 
Against zanamivir there was normal inhibition of the 
virus isolates carrying the H275Y only. Unfortunately 
the virus isolates carrying both the I223R/I and H275Y 
mutations did not display NA activity and the pheno-
typic NA inhibition by oseltamivir and zanamivir could 
not be determined for these isolates.
Discussion
This study describes a case of zanamivir and oseltami-
vir resistant influenza A(H1N1)pdm09 virus investi-
gated in details with the use of NGS. Oseltamivir is 
the drug of choice when treating severely ill patients 
infected with influenza virus. Studies have shown that 
resistance towards oseltamivir develops fast within 
one week of treatment [1]. This coheres with the fact 
that only one mutation (H275Y) is needed to induce 
resistance against oseltamivir in H1N1pdm09 virus 
[21]. Antiviral resistance of influenza viruses against 
zanamivir is more rarely reported than oseltamivir 
resistance. The reason for this is likely due to the more 
extensive use of oseltamivir compared with zanamivir. 
H1N1pdm09 viruses with both I223R and H275Y muta-
tions are shown to have increased resistance against 
both oseltamivir and zanamivir [22]. LeGoff et al. 2012 
[1] shows that I223R alone confers reduced susceptibil-
ity to both oseltamivir and zanamivir and is primarily 
selected by oseltamivir. In this study we observed that 
the I223I/R mutation was selected after the introduc-
tion of zanamivir treatment, whereas the H275Y muta-
tion was induced rapidly after initiation of oseltamivir 
treatment.
In immunocompromised patients the frequency of 
developing antiviral resistance against oseltamivir 
due to the H275Y mutation in connection to treatment 
can reach 13% [23] which is a substantially higher 
frequency compared with overall reporting of resist-
ant H1N1pdm09 viruses which in the 2014/15 season 
was 0.4% [24]. Prolonged shedding of influenza virus 
in immunocompromised patients is well known and 
studies have provided evidence that the prolonged 
virus shedding can result in the emergence of addi-
tional mutations in the NA gene [1,25,26]. This indi-
cates evolution of the viruses and the emergence of 
an increasingly more complex viral population in the 
antiviral-treated patient. This study contributes with 
further data to support this, as additional mutations 
were observed. The additional mutations discovered 
concerned amino acid substitutions both in the active 
and non-active site of the NA molecule, some of which 
have previously been described as involved in antiviral 
resistance, e.g. G147R and S247N [16,18]. In a recent 
published study by Takashita et al. [18] it was reported 
that H1N1pdm09 harbouring dual substitution at posi-
tions H275Y/G147R had a highly reduced inhibition by 
oseltamivir and peramivir, whereas, inhibition was 
within the normal range with zanamivir. The additional 
amino acid changing mutations not earlier described to 
induce antiviral resistance on their own, deserves fur-
ther studies to clarify their potential effect on antiviral 
resistance. It could perhaps be an evolvement toward 
better fitness in the presence of the H275Y and I223R 
mutations under the selection of the antiviral drugs.
All samples were by default investigated by Sanger 
sequencing, however, due to the complex populations 
with mixed nt at important sites for antiviral resist-
ance, NGS was performed to achieve deep sequencing 
and to provide the possibility to investigate minority 
variants. Interestingly, we found a larger proportion 
of minority variants by NGS. Furthermore, many of the 
mixed nt found by Sanger sequencing were confirmed 
by NGS which could additionally reveal the frequency 
of the different amino acid conferred by the nt vari-
ants. This underlines the limitations in interpretation 
of diverse viral populations/quasispecies using Sanger 
sequencing.
The present study emphasises the importance of 
rapid antiviral resistance testing during the course 
of a prolonged infection. The first sample submit-
ted specifically for testing of antiviral resistance was 
obtained 96 days after the first influenza positive 
test. In the meantime the patient had been treated 
with two courses of oseltamivir and zanamivir treat-
ment had been initiated. However, retrospective 
testing showed that the oseltamivir resistance muta-
tion H275Y had been induced already after the first 
oseltamvir treatment, which means that the second 
course of oseltamivir treatment for 2 months had likely 
limited effect on the influenza virus infection. Whether 
an early antiviral resistance test revealing resistance 
towards oseltamivir and a subsequent rapid decision 
to shift to zanamivir could have improved the clear-
ance of infection is however unknown. Studies indicate 
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that immunocompromised patients have a major risk 
for prolonged shedding of influenza virus, and this 
in combination with the questionable effect of antivi-
rals against influenza virus administered later than 48 
hours after symptom onset, makes it difficult to pre-
dict the outcome of treatment [4,27]. Development of 
antiviral resistance in influenza virus in hospitalised 
patients poses a concern for nosocomial transmission, 
and a further risk of spreading mutant viruses. In par-
ticular, the prolonged infections frequently observed in 
immunocompromised patients can foster adaptation 
of increased fitness for viruses harbouring the anti-
viral resistance mutations. Close monitoring of these 
patients and of the development of antiviral resistance 
is necessary, and preventative measures against viral 
transmission both in the hospital setting and in the 
community need to be implemented.
Due to the limited amount of sample material it was 
not possible to investigate the phenotypic antiviral 
resistance characteristics in the NA inhibition assay. 
It is difficult to assess the importance of mixed muta-
tions and the direct effect on antiviral resistance, 
without the opportunity to test in a phenotypic assay. 
From the clinical point of view, the patient’s condition 
did not improve with the administration of antivirals. 
Moreover laboratory testing revealed that the antiviral 
drugs had a limited effect against virus shedding, with 
emergence of resistance against both oseltamivir and 
zanamivir in the viral population infecting the patient. 
During cell propagation new mutations appeared which 
most likely can be attributed to cell adaptation, as the 
original samples did not contain the mutations but 
were represented in the virus isolates only. Cell adap-
tation of influenza viruses during propagation in MDCK 
cells is a normally observed phenomenon [28]. It is 
also problematic to perform phenotypic NA inhibition 
tests requiring virus isolation, when a sample contains 
a mixture of mutated resistant and wild type viruses. 
Indeed, during propagation there is a selection of 
viruses [26] and in this case the wild type virus was 
selected when propagation was performed without 
addition of antivirals to the growth medium. By addi-
tion of antivirals it was possible to rescue viruses with 
the combination of both I223R and H275Y mutations 
but none of the viruses displayed adequate NA activ-
ity to perform NA inhibition test. NA inhibition can be 
further assessed in a plaque reduction assay. However, 
due to limited amount of sample material left, this was 
not an option in our case. The lack of measurable NA 
activity could be due to the modifications of the NA 
protein caused by the induced mutations, even though 
it was possible for the virus to replicate in the cell cul-
tures, or it could be due to remnants of antivirals in the 
cell growth medium interfering with the test.
An interesting finding in the study was the different 
antiviral resistance mutation profiles of two samples 
collected on the same day. The samples were obtained 
from a nasopharyngeal swab and a BAL, respectively, 
and the resistance mutation profiles differed, with the 
BAL sample having a higher frequency of the antiviral 
resistance mutations E119G, I223R and H275Y, whereas 
the nasopharyngeal sample, had a low frequency of 
additional mutations not found in the BAL sample. 
This could indicate a difference in the viral populations 
replicating in the upper and lower respiratory tract, 
respectively. This finding could be of importance when 
considering the sampling site for antiviral resistance 
testing, as the antiviral resistance profile for treatment 
evaluation could be misleading depending on the sam-
pling site. Further studies on the compartmentalisation 
of influenza virus in the infected respiratory tract are 
needed.
Conclusion
The rapidly evolving antiviral resistance observed in 
this case, emphasises the importance of timely anti-
viral resistance testing during treatment of influenza 
virus infection in order to change treatment regime 
and avoid unnecessary administration of ineffective 
medicaments, as well as preventing spread of antiviral 
resistant viruses.
Surveillance of antiviral susceptibility and research in 
the development of antiviral resistance in influenza 
virus is important to prevent the spread of antiviral 
resistant viruses, both in the hospital setting with risk 
group patients, and on a larger scale in the general 
population. The study contributes to the expansion of 
knowledge regarding the complexity of treating immu-
nocompromised patients with antivirals, and the ecol-
ogy of the influenza A(H1N1)pdm09 viral population 
under the selective pressure of antivirals. The study 
furthermore suggests that compartmentalisation of 
antiviral resistant viruses in the respiratory tract is of 
importance for considering the sampling site for antivi-
ral resistance testing.
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